==== Front Mol Med RepMol Med RepMolecular Medicine Reports1791-29971791-3004D.A. Spandidos 2995675510.3892/mmr.2018.9215mmr-18-02-1909ArticlesMicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer Du Binbin 1Wang Xiaoying 1Wu Dewang 1Wang Tao 1Yang Xiongfei 1Wang Jiankai 2Shi Xinlong 1Chen Lingjuan 1Zhang Weisheng 11 Department of Anorectal Surgery, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China2 Department of Radiotherapy, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. ChinaCorrespondence to: Dr Weisheng Zhang, Department of Anorectal Surgery, Gansu Provincial Hospital, 204 Donggang West Road, Chengguan, Lanzhou, Gansu 730000, P.R. China, E-mail: shang9368231908@163.com8 2018 25 6 2018 25 6 2018 18 2 1909 1916 11 7 2017 02 11 2017 Copyright: © Du et al.2018This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.Neoadjuvant chemoradiotherapy (nCRT) following surgery significantly improves the survival rate of patients with rectal cancer. However, nCRT is associated with significant adverse symptoms and high medical costs. Therefore, it is important to investigate potential biomarkers for the prediction of the response to nCRT in patients with rectal cancer. The present study identified candidate biomarkers for predicting a complete response (CR) to nCRT in patients with rectal cancer and investigated the associated mechanisms. Microarray data (accession no. GSE29298) was downloaded from the Gene Expression Omnibus database. Differentially expressed microRNAs (miRNAs/miR) were screened between the pathological CR (pCR) group and no pCR (incomplete response) group. miRNA target genes were predicted using the miRWalk 2.0 online tool and subjected to Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Furthermore, a miRNA co-regulatory network was constructed and disease-associated genes were predicted. The results demonstrated that a total of 36 upregulated and 5 downregulated miRNAs were identified between the two groups. Among these differentially expressed miRNAs, miR-548c-5p, miR-548d-5p and miR-663a were significantly associated with a CR to nCRT. The co-regulatory network and pathway analysis indicated that miR-548c-5p and miR-548d-5p may function together through stem cell pluripotency and ubiquitin-mediated proteolysis signaling pathways. Furthermore, the prediction of disease-associated genes demonstrated that miR-548c-5p/miR-548d-5p and miR-663a may regulate genes associated with rectal cancer, including mutated in colorectal cancers (MCC) and adenomatous polyposis coli (APC), and colorectal neoplasms, including interleukin-6 signal transducer (IL6ST), cell cycle checkpoint kinase 2 (CHEK2), marker of proliferation Ki-67 (MKI67), cadherin 7 (CDH7), calreticulin (CALR) and transforming growth factor β1 (TGFB1). Therefore, miR-548c-5p, miR-548d-5p and miR-663a are promising candidate biomarkers for predicting a CR to nCRT. miR-548c-5p/miR-548d-5p may be associated with a CR by regulating IL6ST, CHEK2, MKI67 and MCC. In addition, it may function through the pluripotency of stem cells and ubiquitin-mediated proteolysis signaling pathways. miR-663a may be associated with a CR to nCRT by targeting CDH7, CALR, APC and TGFβ1. Thus, the miRNA biomarkers investigated in the present study may represent novel therapeutic targets for the prediction and eventual improvement of the response to nCRT in patients with rectal cancer. rectal cancermicroRNAneoadjuvant chemoradiotherapypathological responseprediction ==== Body Introduction Colorectal cancer (CRC) is the third most common type of malignant tumor in the digestive tract and poses a substantial threat to human health worldwide (1). In addition, CRC is the third highest contributor to cancer-associated mortality worldwide, with ~26,580 and 24,790 mortalities annually for males and females, respectively (2). It is reported that ~20% of all patients with CRC are diagnosed with rectal cancer, while ~45% of patients with rectal cancer are further diagnosed with locally advanced rectal cancer (LARC) (3,4). Local recurrence is common in patients with LARC. Neoadjuvant chemoradiotherapy (nCRT) may prevent local recurrence and improve overall survival, and has therefore emerged as the standard treatment for patients with LARC, followed by surgical resection (5). Overall, following nCRT, ~15–20% of patients with LARC demonstrate a complete response (CR), with complete tumor eradication (6–8) while 20% of patients exhibit a poor response to nCRT (9–11). Patients with a CR to nCRT subsequently undergo a simple watch-and-wait procedure or endoscopic resection (12). Patients with a poor response to nCRT are associated with substantial adverse effects and high medical costs (13). Thus, identifying valid predictive biomarkers is of high importance. MicroRNAs (miRNAs/miR) have been proposed as potential biomarkers for predicting the response to treatment and prognosis in rectal cancers. The expression of miR-143 and miR-145 is reported to be significantly upregulated in rectal tumor tissues following treatment, and miR-145 expression demonstrated a close association with tumor regression in patients with rectal cancer (14). Additionally, the distinct expression signatures of miR-16, miR-590-5p and miR-153 in pretreated rectal cancer tissue may predict the response to treatment, miR-519c-3p and miR-561 accurately predict a good or poor response to nCRT in patients with rectal cancer (15). Furthermore, miR-21-5p was demonstrated to be overexpressed in patients with CR (16). However, the role of these biomarkers has not been fully clarified. Della Vittoria Scarpati et al (17), reported a set of 13 miRNAs with specific signatures that were associated with a pathological CR (pCR) to nCRT based on microarray data (accession no. GSE29298). However, the mechanisms of the biomarkers remain unclear. Therefore, the present study downloaded this data from the Gene Expression Omnibus (GEO) database. Based on the miRNA expression profile, differentially expressed miRNAs were identified between pCR and no pCR (incomplete response) groups, and their target genes were predicted, followed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, miRNA co-regulatory network construction and disease-associated gene analysis. The aim of the current study was to investigate specific miRNA signatures as potential biomarkers for predicting a CR to nCRT in rectal cancer and to determine the potential mechanisms of the miRNAs. Materials and methods Data acquisition The miRNA expression profile of GSE29298 (17) was downloaded from the GEO (http://www.ncbi.nlm.nih.gov/geo/), which was sequenced on an Agilent-021827 Human miRNA Microarray platform (Agilent Technologies, Inc., Santa Clara, CA, USA). The miRNA expression profile was analyzed by microarray using fresh frozen biopsies. A total of 38 patients with LARC (cT3-4/N+) were treated with capecitabine-oxaliplatin and pelvic conformal radiotherapy (45cGy) followed by surgery (after 6–8 weeks). Pathological responses were scored according to the tumor regression grade (TRG), as described by Mandard (9). The number of patients with TRG1, TRG2, TRG3 and TRG4 was 9, 16, 10 and 3, respectively. TRG1 indicates pCR, which represents complete tumor regression, while TRG >1 represents an incomplete response (no pCR) with residual tumor cells. Patients were divided into two groups: pCR group (TRG1, n=9) and no pCR group (TRG >1, n=29). Data preprocessing Microarray data were preprocessed using the Bioconductor package (version 3.5) Limma (version 3.28.21) (18), which involved background correction, normalization and expression calculation. The miRNA ID was transformed from the probe ID according to the probe annotation file. The most recent human miRNA annotation file was downloaded from the miRBase Database (19,20) to obtain the miRNA name from the miRNA ID. Identification of differentially expressed miRNAs Differentially expressed miRNAs in the pCR group compared with the no pCR group were identified by non-paired Student's t test analysis and linear models using the Bioconductor package Limma. P<0.05 and|log2 fold change (FC)|≥0.58 were set as the cutoff criteria for differentially expressed miRNAs. Prediction of target genes for differentially expressed miRNAs Target genes regulated by the differentially expressed miRNAs were predicted by ‘validated target module’ using the miRWalk 2.0 online tool (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) (21). KEGG pathway enrichment analysis KEGG pathways enriched in miRNA target genes were analyzed using the clusterProfiler (version 3.3.1) of R package (version 3.3.2) (22). Pathways involving miRNAs were determined. The P-value was calculated using a hypergeometric distribution statistical approach based on the KEGG.db annotation package (version 3.2.3) (23). The cutoff value for a significant pathway was set at P<0.05. miRNA co-regulatory network According to the association between miRNAs and target genes, miRNA-miRNA pairs that regulate the same target genes were screened and an miRNA co-regulatory network was constructed by Cytoscape software (version 3.2.0) (24). Disease-associated gene analysis Marker or therapeutic genes associated with colorectal neoplasms were downloaded from the Comparative Toxicogenomics Database (25). Subsequently, the regulatory network between differentially expressed miRNAs and disease-associated genes was constructed by Cytoscape software (version 3.2.0) (24). Results Differentially expressed miRNAs Following preprocessing, 835 miRNAs were identified and subjected to non-paired Student's t test analysis. According to P<0.05 and |log2FC| ≥0.58, a total of 41 miRNAs were differentially expressed in the pCR group compared with the no pCR group, including 36 upregulated and 5 downregulated miRNAs. The heat map demonstrated that the two groups were distinguished by the expression profiles of 41 differentially expressed miRNAs (Fig. 1). Target genes regulated by differentially expressed miRNAs As indicated in Table I, 3,989 target genes were predicted to be regulated by 41 differentially expressed miRNAs. The results revealed that a single miRNA regulates multiple genes. miR-548c-5p, miR-548d-5p and miR-663a were demonstrated to regulate the greatest number of genes, and were reported to regulate 274, 277 and 127 genes, respectively. Significant KEGG pathways of differentially expressed miRNAs Significant pathways involving the top 11 differentially expressed miRNAs are illustrated in Fig. 2. For miR-548c-5p and miR-548d-5p, the significantly enriched pathways included ‘signaling pathways regulating pluripotency of stem cells’ and ‘ubiquitin-mediated proteolysis’. miRNAs and their co-regulatory target genes A co-regulatory network with 41 nodes and 596 edges was constructed, as demonstrated in Fig. 3. The results indicated that the miR-202-3p/let-7e-5p pairing is responsible for the co-regulation 156 genes, while the miR-548c-5p/miR-548d-5p complex was demonstrated to co-regulate 183 genes, including interleukin (IL)-6 signal transducer (IL6ST), cell cycle checkpoint kinase 2 (CHEK2), mutated in colorectal cancers (MCC), marker of proliferation Ki-67 (MKI6), damage-specific DNA binding protein 1 and actinin α4. Rectal cancer-associated genes A total 33 differentially expressed miRNAs associated with the regulation of rectal cancer-associated genes were analyzed. The regulatory network between 33 miRNAs and 80 marker or therapeutic genes associated with colorectal neoplasms was constructed (Fig. 4). Four genes, including cyclin-dependent kinase inhibitor 1B (CDKN1B), adenomatous polyposis coli (APC), MCC and interferon β1 (IFNB1), were demonstrated to be associated with rectal cancer. The following seven miRNAs were identified as regulators of the four rectal cancer-associated genes: miR-548c-5p/miR-548d-5p (MCC), miR-663a (APC), miR-149-3p (CDKN1B), miR-1909-5p (CDKN1B), miR-494-3p (MCC) and miR-26a-5p (IFNB1). Specifically, the miR-548c-5p/miR-548d-5p complex was reported to co-regulate IL6ST, CHEK2, MCC and MKI67, and miR-663a was demonstrated to regulate cadherin 7 (CDH7), calreticulin (CALR), APC and transforming growth factor (TGF) β1 (TGFB1). Discussion It was previously reported that nCRT improves the outcome of patients with rectal cancer; however, not all patients benefit from this treatment (15). Thus, identifying predictive molecular biomarkers is of clinical importance (16). The present study aimed to identify specific miRNAs as predictive biomarkers based on their expression profiles. Furthermore, the potential underlying mechanisms of the biomarkers involved in the response to nCRT were investigated. In the current study, 36 upregulated and 5 downregulated miRNAs were detected between pCR and no pCR (incomplete response) groups. KEGG pathway analysis demonstrated that the differentially expressed miR-134-5p and miR-630 were significantly associated with the ‘HIF-1 signaling pathway’. Hypoxia-inducible factor (HIF)-1 is a transcription factor that affects gene expression by regulating oxygen delivery and deprivation (26). In addition, the activation of the HIF pathway is reported to contribute to tumor growth. Clinical evidence demonstrated that HIF-1 was overexpressed in patients with a poor prognosis in various cancer types (27). In the present study, miR-134-5p and miR-630 were demonstrated to be significantly upregulated in patients that exhibited a CR to nCRT. The expression of miRNA is negatively associated with the expression of its target genes. Thus, the target genes involved in the HIF-1 signaling pathway were significantly downregulated in CR cases, which may inhibit the HIF-1 signaling pathway and contribute to tumor regression. These results indicated that the bioinformatic findings were promising in the present study. Additionally, three miRNAs among the top 11 miRNAs, including miR-548c-5p, miR-548d-5p and miR-663a, were demonstrated to regulate genes associated with colorectal neoplasms. It has been previously reported that miR-548c-5p inhibited the proliferation, migration and invasion, and promoted the apoptosis, of liver cancer stem-like cells (28). In addition, miRNA-548d-5p was reported to have a complementary role in supporting oncogenicity in cervical cancer (29). However, few studies have reported the association between these two miRNAs and rectal cancer. Co-regulatory network analysis indicated that miR-548c-5p and miR-548d-5p may function as a complex to co-regulate four genes associated with colorectal neoplasms, including IL6ST, CHEK2, MKI67 and MCC. High IL-6 cytokine levels were previously reported to be associated with an advanced stage of disease and decreased survival of patients with CRC (30). A previous study demonstrated that IL6ST mediated tumor cell proliferation and apoptosis through glycoprotein 130 activation, with subsequent signaling through signal transducer and activator of transcription 3 in CRC (31). CHEK2 is a tumor suppressor that functions in the p53 pathway of the DNA damage response (32). The CHEK2 variants I157T and 1100delC were reported to increase the risk of CRC (33,34). MKI67 encodes a nuclear protein that is strictly associated with cellular proliferation, which means it is regarded as a proliferative marker (35). Antigen Ki-67, encoded by MKI67, is reported to be highly expressed in proliferative cells (36) and a previous study demonstrated that increased Ki-67 expression post-therapy was associated with improved disease-free survival in patients with rectal cancer (37). In addition, another study reported that the extent of the tumor response to nCRT was closely associated with the expression level of Ki-67 (38). Therefore, the expression of Ki-67 may be a potential biomarker for predicting the radiosensitivity of tumors for CRT in rectal cancers. A colorectal mutant cancer protein encoded by MCC, located on chromosome 5q21, was identified as a tumor suppressor gene and is considered to negatively regulate cell cycle progression (39). Allele loss in MCC is common in CRC (40). These findings indicate that miR-548c-5p and miR-548d-5p may be involved in the mechanism of the CR to nCRT by targeting genes associated with cell proliferation, DNA damage and the cell cycle. Furthermore, KEGG pathway analysis revealed that ‘signaling pathways regulating pluripotency of stem cells’ and ‘ubiquitin-mediated proteolysis’ signaling pathways were significantly enriched for the miR-548c-5p/miR-548d-5p complex. Cancer stem cells have the capacity for tumor initiation by differentiating into heterogeneous lineages of cancer cells (41). The ubiquitin-dependent proteolysis system is involved in the regulation β-catenin turnover (42) and it is established that the accumulation of β-catenin leads to the transcription of pre-oncogenes (43). These findings indicate that the miR-548c-5p/miR-548d-5p complex may contribute to the CR to nCRT through the pluripotency of stem cells and ubiquitin-mediated proteolysis pathways. It was previously reported that miR-663 exhibited an anti-cancer effect by targeting the TGFB1 transcript through the TGFβ signaling pathway in SW480 human colon cancer cells (44), which is consistent with the results of the present study. In the present study, three other genes associated with colorectal neoplasms were demonstrated to be regulated by miR-663a, including CDH7, CALR and APC. Furthermore, E-cadherin (CDH1), a member of the CDH family, determines cell-cell adhesion and increases the nuclear translocation of β-catenin (44,45). It is well-document that the APC protein, encoded by APC, prevents the accumulation of β-catenin, a key factor in cancer (46). CDH7 is also a member of the CDH family (47). Thus, it can be suggested that miR-663a may function by altering the levels of β-catenin through targeting CDH7 and APC. Calreticulin, encoded by CALR, was reported to be associated with the infiltration of T-cells, and low expression of CALR may represent a novel mechanism underlying immune escape in colon cancer (48). Thus, miR-663a may be closely associated with a CR to nCRT by targeting these four genes. The aforementioned results support the predictive roles of miR-548c-5p, miR-548d-5p and miR-663a in the response of patients with rectal cancer to nCRT. The present study further analyzed the miRNA microarray data developed from patients treated with capecitabine-oxaliplatin and pelvic conformal radiotherapy (45 cGy) followed by surgery (after 6–8 weeks). Due to the lack of the clinical samples under the same conditions, experimental validations were not available, which is a limitation of the present study. Thus, evaluations in larger, prospective trials are required to validate these biomarkers. In conclusion, miR-548c-5p, miR-548d-5p and miR-663a are potential biomarkers for predicting a CR to nCRT in rectal cancer. The miR-548c-5p/miR-548d-5p complex may function by targeting IL6ST, CHEK2, MKI67 and MCC. In addition, this complex may function through the pluripotency of stem cells and ubiquitin-mediated proteolysis signaling pathways. miR-663a may affect the tumor response to treatment by regulating CDH7, CALR, APC and TGFB1. Furthermore, targeting these miRNAs with oligonucleotides may represent a potential therapy for improving a poor response to nCRT in patients with rectal cancer. Acknowledgements Not applicable. Funding The present study was supported by the Bureau of Science and Technology of Innovation and Entrepreneurship Project (Lanzhou, China; grant no. 2015-RC-37). Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Authors' contributions BD and WZ were responsible for the conception and design of the present study. JW and LC acquired the data. XW and DW analyzed and interpreted the data. TW, XS and DW performed the statistical analyses. XY, DW and LC were involved in conception of the research, participated in its design and coordination and aided the writing of the manuscript. All authors read and approved the final manuscript. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Figure 1. Heatmap for differentially expressed miRNAs. The pink bar represents the pCR group and the green bar represents the no pCR group. miR/miRNA, microRNA; nCRT, neoadjuvant chemoradiotherapy; pCR, complete response to nCRT; no pCR, incomplete response to nCRT. Figure 2. Enriched pathways for the top 11 differentially expressed miRNAs. Different dot color and dot size represent the P-value and gene ratio, respectively. The number below each miRNA name represents the number of target genes involved in pathway analysis. miR/miRNA, microRNA; STAT, signal transducer and activator of transcription; HIF, hypoxia inducible factor; EGFR, epidermal growth factor receptor; HTLV, human T-lymphotropic virus; TGF, transforming growth factor. Figure 3. Co-regulatory network among miRNAs. Grey filled ovals represent downregulated miRNA and non-filled ovals represent upregulated miRNA in the pCR group compared with the no pCR group. miR/miRNA, microRNA; nCRT, neoadjuvant chemoradiotherapy; pCR, complete response to nCRT; no pCR, incomplete response to nCRT. Figure 4. Regulatory network between miRNAs and target genes associated with colorectal neoplasms. Diamonds represent target genes, with pink diamonds representing genes associated with rectal cancer and all other genes being associated with colorectal neoplasms. Grey filled ovals represent downregulated miRNA and non-filled ovals represent upregulated miRNA in the pCR group compared with the no pCR group. miR/miRNA, microRNA; nCRT, neoadjuvant chemoradiotherapy; pCR, complete response to nCRT; no pCR, incomplete response to nCRT; MCC, mutated in colorectal cancers; CDKN1B, cyclin-dependent kinase inhibitor 1B; IFNB1, interferon β1; APC, adenomatous polyposis coli; MKI67, marker of proliferation Ki-67; IL6ST, interleukin-6 signal transducer; CHEK2, cell cycle checkpoint kinase 2; CDH7, cadherin 7; CALR, calreticulin; TGFB1, transforming growth factor β1. Table I. Target genes regulated by microRNAs in pathological complete response group compared with the pathological incomplete response group. A, Upregulated miRNAs miRNA Target gene count hsa-miR-1183 108 hsa-miR-1224-5p   84 hsa-miR-1246   52 hsa-miR-125a-3p 292 hsa-miR-1268a   49 hsa-miR-134-5p   95 hsa-miR-1471     3 hsa-miR-188-5p 136 hsa-miR-483-5p 145 hsa-miR-548c-5p 274 hsa-miR-548d-5p 277 hsa-miR-575 141 hsa-miR-622 118 hsa-miR-630   83 hsa-miR-659-3p   68 hsa-miR-663a 127 hsa-miR-671-5p 164 hsa-miR-765 355 hsa-miR-1182   82 hsa-miR-1207-5p 223 hsa-miR-1225-5p   49 hsa-miR-1226-5p   78 hsa-miR-1275 155 hsa-miR-1299   84 hsa-miR-149-3p 733 hsa-miR-150-3p   44 hsa-miR-1909-5p   50 hsa-miR-1914-3p 117 hsa-miR-202-3p 253 hsa-miR-370-3p 111 hsa-miR-371a-5p 324 hsa-miR-494-3p 154 hsa-miR-557 207 hsa-miR-584-5p   79 hsa-miR-601   18 hsa-miR-623 262 B, Downregulated miRNAs miRNA Target gene count hsa-let-7e-5p 711 hsa-miR-1260a 170 hsa-miR-192-3p 149 hsa-miR-26a-5p 541 hsa-miR-30b-5p 477 miR/miRNA, microRNA. ==== Refs References 1 Zheng S Cai S Colorectal cancer epidemiology and prevention study in China Chinese-German J Clinical Oncol 2 72 75 2003 10.1007/BF02855647 2 Jemal A Bray F Center MM Ferlay J Ward E Forman D Global cancer statistics CA Cancer J Clin 61 69 90 2011 10.3322/caac.20107 21296855 3 Jemal A Siegel R Ward E Hao Y Xu J Murray T Thun MJ Cancer statistics, 2008 CA Cancer J Clin 58 71 96 2008 10.3322/CA.2007.0010 18287387 4 Dusek L Muzik J Kubasek M Koptikova J Zaloudik J Vyzula R Epidemiology of Malignant Tumours in the Czech Republic http://www.svod.cz 9 12 2013 5 Krook JE Moertel CG Gunderson LL Wieand HS Collins RT Beart RW Kubista TP Poon MA Meyers WC Mailliard JA Effective surgical adjuvant therapy for high-risk rectal carcinoma N Engl J Med 324 709 715 1991 10.1056/NEJM199103143241101 1997835 6 Valentini V Aristei C Glimelius B Minsky BD Beets-Tan R Borras JM Haustermans K Maingon P Overgaard J Pahlman L Multidisciplinary rectal cancer management: 2nd european rectal cancer consensus conference (EURECA-CC2) Radiother Oncol 92 148 163 2009 10.1016/j.radonc.2009.06.027 19595467 7 Gérard JP Conroy T Bonnetain F Bouché O Chapet O Closon-Dejardin MT Untereiner M Leduc B Francois E Maurel J Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203 J Clin Oncol 24 4620 4625 2006 10.1200/JCO.2006.06.7629 17008704 8 Engels B Gevaert T Sermeus A Ridder MD Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer Front Oncol 2 47 2012 10.3389/fonc.2012.00047 22655273 9 Mandard AM Dalibard F Mandard JC Marnay J Henry-Amar M Petiot JF Roussel A Jacob JH Segol P Samama G Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73 2680 2686 1994 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C 8194005 10 Martin ST Heneghan HM Winter DC Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer Br J Surg 99 918 928 2012 10.1002/bjs.8702 22362002 11 Suárez J Vera R Balén E Gómez M Arias F Lera JM Herrera J Zazpe C Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer Colorectal Dis 10 563 568 2008 10.1111/j.1463-1318.2007.01424.x 18070184 12 Azizian A Gruber J Ghadimi BM Gaedcke J MicroRNA in rectal cancer World J Gastrointest Oncol 8 416 426 2016 10.4251/wjgo.v8.i5.416 27190581 13 Svoboda M Sana J Fabian P Kocakova I Gombosova J Nekvindova J Radova L Vyzula R Slaby O MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients Radiat Oncol 7 195 2012 10.1186/1748-717X-7-195 23167930 14 Drebber U Lay M Wedemeyer I Vallböhmer D Bollschweiler E Brabender J Mönig SP Hölscher AH Dienes HP Odenthal M Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy Int J Oncol 39 409 415 2011 21567082 15 Kheirelseid EA Miller N Chang KH Curran C Hennessey E Sheehan M Newell J Lemetre C Balls G Kerin MJ miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy Int J Colorectal Dis 28 247 260 2013 10.1007/s00384-012-1549-9 22903298 16 Lopes-Ramos CM Habr-Gama A Bde Quevedo S Felício NM Bettoni F Koyama FC Asprino PF Galante PA Gama-Rodrigues J Camargo AA Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients BMC Med Genomics 7 68 2014 10.1186/s12920-014-0068-7 25496125 17 Della Vittoria Scarpati G Falcetta F Carlomagno C Ubezio P Marchini S De Stefano A Singh VK D'Incalci M De Placido S Pepe S A Specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 83 1113 1119 2012 10.1016/j.ijrobp.2011.09.030 22172905 18 Smyth BGK Limma: Linear models for microarray data Bioinformatics and Computational Biology Solutions Using R and Bioconductor Springer 397 420 2005 10.1007/0-387-29362-0_23 19 Griffiths-Jones S miRBase: The microRNA sequence database Methods Mol Biol 342 129 138 2006 16957372 20 Griffiths-Jones S miRBase: microRNA sequences and annotation Curr Protoc Bioinformatics 29 12.9.1 12.9.10 2010 21 Dweep H Gretz N miRWalk2.0: A comprehensive atlas of microRNA-target interactions Nat Methods 12 697 2015 10.1038/nmeth.3485 26226356 22 Yu G Wang LG Han Y He QY clusterProfiler: An R package for comparing biological themes among gene clusters OMICS 16 284 287 2012 10.1089/omi.2011.0118 22455463 23 Maqbool A Lattke M Wirth T Baumann B Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging Mol Neurodegener 8 40 2013 10.1186/1750-1326-8-40 24119288 24 Kohl M Wiese S Warscheid B Cytoscape: Software for visualization and analysis of biological networks Methods Mol Biol 696 291 303 2011 10.1007/978-1-60761-987-1_18 21063955 25 Davis AP Grondin CJ Lennonhopkins K Saraceni-Richards C Sciaky D King BL Wiegers TC Mattingly CJ The Comparative Toxicogenomics Database's 10th year anniversary: Update 2015 Nucleic Acids Res 43 (Database issue) D914 D920 2015 10.1093/nar/gku935 25326323 26 Semenza GL HIF-1 and mechanisms of hypoxia sensing Curr Opin Cell Biol 13 167 171 2001 10.1016/S0955-0674(00)00194-0 11248550 27 Jaakkola P Mole DR Tian YM Wilson MI Gielbert J Gaskell SJ von Kriegsheim A Hebestreit HF Mukherji M Schofield CJ Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Science 292 468 472 2001 10.1126/science.1059796 11292861 28 Fang L Zhang HB Li H Fu Y Yang GS miR-548c-5p inhibits proliferation and migration and promotes apoptosis in CD90(+) HepG2 cells Radiol Oncol 46 233 241 2015 29 Mandal P Bhattacharjee B Das Ghosh D Mondal NR Chowdhury Roy R Roy S Sengupta S Differential expression of HPV16 L2 gene in cervical cancers harboring episomal HPV16 genomes: Influence of synonymous and non-coding region variations PLoS One 8 e65647 2013 10.1371/journal.pone.0065647 23762404 30 Knüpfer H Preiss R Serum interleukin-6 levels in colorectal cancer patients-a summary of published results Int J Colorectal Dis 25 135 140 2010 10.1007/s00384-009-0818-8 19898853 31 Waldner MJ Foersch S Neurath MF Interleukin-6-A Key regulator of colorectal cancer development Int J Biol Sci 8 1248 1253 2012 10.7150/ijbs.4614 23136553 32 Kilpivaara O Laiho P Aaltonen LA Nevanlinna H CHEK2 1100delC and colorectal cancer J Med Genet 40 e110 2003 10.1136/jmg.40.10.e110 14569133 33 Meijers-Heijboer H Wijnen J Vasen H Wasielewski M Wagner A Hollestelle A Elstrodt F van den Bos R de Snoo A Fat GT The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype Am J Hum Genet 72 1308 1314 2003 10.1086/375121 12690581 34 Kilpivaara O Alhopuro P Vahteristo P Aaltonen LA Nevanlinna H CHEK2 I157T associates with familial and sporadic colorectal cancer J Med Genet 43 e34 2006 10.1136/jmg.2005.038331 16816021 35 Hofstädter F Knüchel R Rüschoff J Cell proliferation assessment in oncology Virchows Arch 427 323 341 1995 10.1007/BF00203402 7496604 36 Dalerba P Kalisky T Sahoo D Rajendran PS Rothenberg ME Leyrat AA Sim S Okamoto J Johnston DM Qian D Single-cell dissection of transcriptional heterogeneity in human colon tumors Nat Biotechnol 29 1120 1127 2011 10.1038/nbt.2038 22081019 37 Rau B Sturm I Lage H Berger S Schneider U Hauptmann S Wust P Riess H Schlag PM Dörken B Daniel PT Dynamic Expression Profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy J Clin Onco 21 3391 3401 2003 10.1200/JCO.2003.07.077 38 Kim NK Park JK Lee KY Yang WI Yun SH Sung J Min JS p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer Ann Surg Oncol 8 418 424 2001 10.1007/s10434-001-0418-5 11407516 39 Kinzler KW Nilbert MC Vogelstein B Bryan TM Levy DB Smith KJ Preisinger AC Hamilton SR Hedge P Markham A Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers Science 251 1366 1370 1991 10.1126/science.1848370 1848370 40 Cawkwell L Lewis FA Quirke P Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction Br J Cancer 70 813 818 1994 10.1038/bjc.1994.404 7947085 41 Kong D Li Y Wang Z Sarkar FH Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel) 3 716 729 2011 10.3390/cancers30100716 21643534 42 Aberle H Bauer A Stappert J Kispert A Kemler R beta-catenin is a target for the ubiquitin- proteasome pathway EMBO J 16 3797 3804 1997 10.1093/emboj/16.13.3797 9233789 43 Morin PJ Sparks AB Korinek V Barker N Clevers H Vogelstein B Kinzler KW Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 1787 1790 1997 10.1126/science.275.5307.1787 9065402 44 Zhu L Chen H Zhou D Li D Bai R Zheng S Ge W MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility Med Oncol 29 1037 1043 2012 10.1007/s12032-011-9975-z 21562850 45 Schmalhofer O Brabletz S Brabletz T E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer Cancer Metastasis Rev 28 151 166 2009 10.1007/s10555-008-9179-y 19153669 46 Munemitsu S Albert I Souza B Rubinfeld B Polakis P Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein Proc Natl Acad Sci USA 92 3046 3050 1995 10.1073/pnas.92.7.3046 7708772 47 Gul IS Hulpiau P Saeys Y Van RF Evolution and diversity of cadherins and catenins Exp Cell Res 358 3 9 2017 10.1016/j.yexcr.2017.03.001 28268172 48 Peng RQ Chen YB Ding Y Zhang R Zhang X Yu XJ Zhou ZW Zeng YX Zhang XS Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer World J Gastroenterol 16 2428 2434 2010 10.3748/wjg.v16.i19.2428 20480531